Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial.
Shohdy KS, Pillai M, Abbas KS, Allison J, Waddell T, Darlington E, Mohammad S, Hood S, Atkinson S, Simpson K, Morgan D, Nathan P, Kilgour E, Dive C, Thistlethwaite F.
Shohdy KS, et al. Among authors: atkinson s.
Immunooncol Technol. 2024 Mar 18;22:100712. doi: 10.1016/j.iotech.2024.100712. eCollection 2024 Jun.
Immunooncol Technol. 2024.
PMID: 38694705
Free PMC article.